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AJH 2006; 19:782–787Background: Fabry disease is a rare X-linked disease
arising from deficiency of -galactosidase A. It results in
early death related to renal, cardiac, and cerebrovascular
disease, which are also important outcomes in patients
with elevated blood pressure (BP). The prevalence of
uncontrolled hypertension, as well as the effect of enzyme
replacement therapy on BP, in patients with Fabry disease
is unknown.
Methods: We examined uncontrolled hypertension
(systolic BP [SBP] 130 mm Hg or diastolic BP [DBP]
80 mm Hg) among 391 patients with Fabry disease who
were participating in the Fabry Outcome Survey (FOS).
Results: Uncontrolled hypertension was present in 57%
of men and 47% of women. In patients with chronic
kidney disease (CKD) stage 1 (n100), median SBP was
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doi:10.1016/j.amjhyper.2006.01.011120 mm Hg and median DBP was 74 mm Hg. In patients
with CKD stage 2 (n172), median SBP was 125 mm Hg
and median DBP was 75 mm Hg. In patients with CKD
stage 3 (n63), median SBP was 130 mm Hg and median
DBP was 75 mm Hg. There was a significant decrease in
both SBP and DBP during a 2-year course of enzyme
replacement therapy.
Conclusions: This study revealed a high prevalence of
uncontrolled hypertension among patients with Fabry dis-
ease. Thus there is a need to improve BP control and
renoprotection in patients with Fabry disease. Am J Hy-
pertens 2006;19:782–787 © 2006 American Journal of
Hypertension, Ltd.
KeyWords: Blood pressure, Fabry disease, glomerular
filtration rate, hypertension, reno-protection.F abry disease is a rare X-linked lysosomal storagedisease. Deficient activity of -galactosidase A1results in progressive accumulation of globotriao-
sylceramide (Gb3) in blood vessels, the kidneys, and the
heart.2 In childhood, patients present with acroparesthesia,
fever, angiokeratoma, hypohidrosis, corneal and lenticular
opacities, and diarrhea. Later on, Gb3 accumulation leads
to end-stage renal disease, left ventricular hypertrophy,
cerebrovascular disease, and premature death. In contrast
to many other diseases with X-linked inheritance, most
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protective therapy with angiotensin-converting enzyme in-
hibitors (ACEi) or angiotensin II–receptor blockers (ARB)
or both, should be accomplished in the majority of the
patients. The prevalence of uncontrolled hypertension (ie,
systolic BP [SBP] 130 or diastolic BP [DBP] 80 mm
Hg) in patients with Fabry disease is unknown. Our aim
was therefore to analyze BP control in patients with Fabry
disease.
Methods
Design
In a cross-sectional study we examined the prevalence of
uncontrolled hypertension among adult patients with Fabry
disease who are included in a large international database,
that of the Fabry Outcome Survey (FOS).9
FOS
The FOS database has been approved by the institu-
tional review board of participating centers, and all
patients gave written informed consent. At the time of
this analysis (March 2004), FOS contained data from
545 patients. On enrollment in FOS, each patient’s
medical history is documented, including the year of
diagnosis of Fabry disease, signs and symptoms of the
disease (cerebrovascular, neurologic, psychiatric, ear,
eye, cardiac, BP, vascular, respiratory, renal, gastroin-
testinal, genital, musculoskeletal, dermatologic, endocri-
nologic, and general symptoms), treatment, demographic
characteristics, and family history. Results of measurements
performed routinely in clinical practice, including office mea-
surement of BP or clinical chemistry analyses, can be entered
in the database. Anonymous data are submitted electronically
by participating physicians to the central FOS database.
Definition of Uncontrolled
BP, Kidney Function, and
Stages of Chronic Kidney Disease
We defined uncontrolled hypertension as SBP 130 mm
Hg or DBP 80 mm Hg, which is the threshold for BP
control in renal disease.6,8
For assessment of renal function, the glomerular filtra-
tion rate (GFR) was estimated using the short Modification
of Diet in Renal Disease (MDRD) formula.10 Renal func-
tion was classified according to the National Kidney Foun-
dation’s Kidney Disease Outcomes Quality Initiative (K/
DOQI) guidelines.11 The definition of chronic kidney
disease (CKD) was as follows: stage 1, estimated GFR
(eGFR) 90 mL/min/1.73 m2; stage 2, eGFR 60 to 89
mL/min/1.73 m2; stage 3, eGFR 30 to 59 mL/min/1.73 m2;
stage 4, eGFR 15 to 29 mL/min/1.73 m2; stage 5, 15
mL/min/1.73 m2or the patient undergoing dialysis.
ERT
The enzyme -galactosidase A is a homodimer and each
monomer is composed of 398 amino acid residues and hasan active site. Two aspartic acid residues in position 170
and 231 determine the catalytic reaction that releases the
galactose bound to the  component of the substrate of the
enzyme. Agalsidase alfa (Replagal, TKT Europe 5S/Shire
Human Genetic Therapies) is a protein synthesized in a
continuous line of human fibroblasts by a process of in situ
activation of transcription of the GLA gene. The peptide
sequence is identical to human -galactosidase A. Agal-
sidase alfa is administered intravenously every 2 weeks in
a dose of 0.2 mg/kg body weight.
Statistical Analysis
Data are given as medians (10th percentile; 90th percen-
tile). We used logistic regression analysis to assess inde-
pendent associations of age, sex, and renal function
(eGFR) with the presence of uncontrolled hypertension of
patients with Fabry disease who were not on renal replace-
ment therapy, and provide odds ratios (OR) with corre-
sponding 95% confidence intervals (CI).
Longitudinal follow-up of BP from baseline, to 12
months, and to 24 months of enzyme replacement therapy
(ERT) was performed using individual patients’ median
values reported at 3 to 3 months around the start of ERT
for baseline, 9 to 15 months after the start of ERT, and 21
to 27 months after the start of ERT, respectively. Statisti-
cal analyses were performed using Wilcoxon rank-sum
and Kruskal-Wallis tests.
Results
Patients
Among 545 patients (463 adults, 82 children) with Fabry
disease who were registered in FOS as of March 2004, a
total of 391 adults (including patients undergoing dialysis
and those with kidney transplants; age 18 years; 179
female and 212 male) had BP readings entered in the
database. The patient distribution is summarized in a flow-
chart in Fig. 1. Table 1 lists demographic and clinical
characteristics of the patients.
The median SBP among the 179 female subjects (me-
dian age: 43.9 [23.3; 62.3] years) was 123 (108; 145) mm
545 patients with Fabry 
disease enrolled in FOS82 children
278 with any concomitant 
therapy reported
463 adults 252 on ERT
391 adults with blood 
pressure readings
88 on ERT for
> 2 years
60 with blood pressure
readings at baseline and 
after 1 & 2 years of ERT
342 with eGFR 
(w.o. dialysis or
transplants)
271 with blood pressure readings 
and with concomitant therapy 
reported
FIG. 1. Distribution of study subjects. eGFR  estimated glomeru-
lar filtration rate; ERT enzyme replacement therapy; FOS Fabry
Outcome Survey.
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SBP of the 212 male subjects (median age: 35.1 [23.1;
51.7] years) was 125 (110; 148) mm Hg and the median
DBP was 76 (65; 86) mm Hg.
Of the subjects 205 (52.4%) had uncontrolled hyper-
tension (57.1% [121/212] male; 46.9% [84/179] female).
Renal Function and BP
Among 391 patients for whom BP readings were avail-
able, GFR estimates or information on renal replacement
therapy were entered into the database for 376. In patients
with CKD stage I, median SBP was 120 (110; 137) mm
Hg and median DBP was 74 (64; 83) mm Hg (n100). In
patients with CKD stage II, median SBP was 125 (110;
145) mm Hg and median DBP was 75 (63; 85) mm Hg
(n172). In patients with CKD stage III, median SBP was
130 (110; 148) mm Hg and median DBP was 75 (65; 88)
mm Hg (n63). The proportion of female and male patients
with uncontrolled hypertension according to eGFR class
and of those who were undergoing dialysis or had received
a renal transplant is indicated in Table 2.
Age (per year; OR  1.036; 95% CI  1.014 to 1.057)
and female sex (OR  0.576; 95% CI  0.360 to 0.922),
Table 1. Baseline demographic data of 391 patien
and of 60 patients who had enzyme replacement the
Characteristic
Patients with
(n 
Sex (female) 179 (45.
Age (y) 40 (24,
Age at diagnosis (y) 32.0 (13,
SBP (mm Hg) 124 (110
DBP (mm Hg) 75 (64,
Uncontrolled hypertension 205 (52.
Stage I hypertension 63 (16.
Stage II hypertension 12 (3.1
Serum creatinine (mg/dL) 0.98 (0.7
eGFR (mL/min/1.73m2) 79 (53,
BMI (kg/m2) 23 (19,
BMI  body mass index; DBP  diastolic blood pressure; eGFR  e
Data are given as medians and 10th/90th centile, or as counts a
* n  342 (dialysis patients and transplant patients excluded).
† n  54 (dialysis patients and transplant patients excluded).
Table 2. Proportion of female and male patients wit
to class of estimated glomerular filtration rate (eGF
received a kidney transplant
eGFR* Men
90 37% (27/73)
60–89 60% (40/67)
30–60 67% (16/24)
30 100% (7/7)
Dialysis 55% (6/11)
Transplant 86% (19/22)
Overall 56% (115/204)but not eGFR (per mL/min/1.73 m2; OR  0.991; 95% CI
 0.980 to 1.003) were independently associated with
uncontrolled hypertension of patients who were not on
renal replacement therapy (n  342). Exluding 105 pa-
tients who used antihypertensive therapy did not materi-
ally change the results of this analysis.
Blood Pressure During ERT
Blood pressure readings were available before the start of
ERT (0.66 to 0.0 months before start of ERT), and at 12
months and 24 months of therapy with agalsidase alfa for
60 adult patients (Table 1). Uncontrolled hypertension was
present in 66.7% at baseline, in 46.7% after 12 months and
in 38.3% after 24 months of ERT.
The decrease in SBP and DBP after 24 months of ERT
was statistically significant (P  .05) (Fig. 2).
Renal Function During ERT
Among the 60 patients receiving ERT for 2 years and
who had BP readings entered in the database, eGFR was
reported in 54 patients (three dialysis and three transplant
patients excluded). In these patients the median eGFR
ith blood pressure readings entered in the database
y (ERT)
ry disease
)
Patients who received ERT
(n  60)
15 (25.0)
36 (23, 49)
28 (13, 45)
5) 130 (110, 150)
77 (61, 91)
40 (66.7)
16 (26.7)
4 (6.7)
.38)* 0.97 (0.80, 1.39)†
)* 88 (49, 126)†
22 (18, 27)
ted glomerular filtration rate; SBP  systolic blood pressure.
equencies.
bry disease and uncontrolled hypertension according
in those undergoing dialysis and in those who had
Women Total
33% (9/27) 36% (36/100)
50% (52/105) 53% (92/172)
56% (22/39) 60% (38/63)
0 100% (7/7)
0 55% (6/11)
0% (0/1) 83% (19/23)ts w
rap
Fab
391
8)
58)
50)
, 14
85)
4)
1)
)
7, 1
109
29)
stima
nd frh Fa
R),48% (83/172) 53% (198/376)
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min/1.73 m2 at baseline, 86 mL/min/1.73 m2 after 1 year
of treatment, and 84 mL/min/1.73 m2 after 2 years of
treatment).
Use of Antihypertensive
Drugs in Patients With Fabry Disease
Overall the use of concomitant therapy was reported in
309 of 545 patients in the FOS database (278 of 465
adults). Of these 309 patients, 135 were reported to use
antihypertensive drugs. The number of patients using dif-
ferent classes of antihypertensive agents is indicated in
Fig. 3. Among 20 kidney transplant recipients, concomi-
tant therapy was reported in 17 cases.
Among the 205 patients with uncontrolled hyperten-
sion, concomitant therapy was indicated in 137 patients
(63 [45%] used no antihypertensive agents, 35 used one,
21 used two, and 18 used three or more different antihy-
pertensive drugs).
Among patients with a BP  130/80 mm Hg, concom-
itant therapy was indicated in 134 patients (79 [59%]
patients used no antihypertensive agents, 32 used 1, 11
used two, and 12 used three or more different antihyper-
tensive drugs).
Overall, 77 of the 309 patients were prescribed an
ACEi or an ARB or both. Among the patients with an
eGFR of90 mL/min/1.73 m2, 58 (21%) used an ACEi or
ARB or both.
Use of Antihypertensive Drugs During ERT
Among the 60 patients in whom data for 24 months of
ERT were available, four had no concomitant therapy
entered in the database. Reports on antihypertensive treat-
ment were available in 29 of these 60 patients, and in 10
of these patients antihypertensive treatment was started
FIG. 2. Systolic and diastolic blood pressure of 60 patients with
Fabry disease before, and at 12 and 24 months of enzyme replace-
ment therapy.after the initiation of ERT.Discussion
The major complications of hypertension include myo-
cardial infarction, heart failure, stroke, and kidney fail-
ure. For instance, each increment of 20 mm Hg in SBP
or 10 mm Hg in DBP doubles the risk of cardiovascular
disease.12
From the Multiple Risk Factor Intervention Trial
(MRFIT) involving 332,544 men, we know that the risk
for end-stage renal disease increases continuously across
the different BP categories. An SBP 210 mm Hg or a
DBP120 mm Hg confers a 22.1-fold increase in relative
risk for end-stage renal disease as compared with an SBP
120 mm Hg and a DBP 80 mm Hg.13
Uncontrolled hypertension (BP 130/80 mm Hg) was
present in 52.4% of our patients. A meta-analysis revealed
that the prevalence of hypertension (140/90 mm Hg)
among the general European population was 44.2%,14 and
the prevalence of hypertension increases in parallel with
the decline of eGFR.11 Although the threshold for diag-
nosis of hypertension in the latter study of the general
population and uncontrolled hypertension in our study
differs, our data indicate that hypertension treatment in
Fabry disease, where most of the patients are cared for by
tertiary referral centers, is suboptimal. This is of partic-
ular interest, because men with Fabry disease are known
to have a lifespan of approximately 50 years (about 20
years below average).15 Among women with Fabry
disease life expectancy is also significantly decreased
compared with that in the general population.3 Further-
more survival in patients undergoing dialysis is signif-
icantly shorter in those with Fabry disease than in those
with other primary nephropathies.16 The most common
causes of death are renal failure and cerebrovascular
events. The latter most often occur in the vertebrobasi-
lar territory and are associated with a high recurrence
rate and death.
FIG. 3. Numbers of patients using individual classes of antihyper-
tensive drugs (from 134 patients for whom antihypertensive ther-
apy was reported in the Fabry Outcome Study [FOS]), according to
chronic kidney disease (CKD) stage. ACEi  angiotensin-converting
enzyme inhibitors; ARB  angiotensin II receptor blockers; BB 
-blockers; CCB  calcium channel blockers; D  diuretics.
786 AJH–August 2006–VOL. 19, NO. 8HYPERTENSION IN FABRY DISEASEData on hypertension or BP control in patients with
Fabry disease are scarce. A group of 105 male patients
with Fabry disease examined by Branton et al showed a
low prevalence of hypertension (30%), and among these
patients only 36% (10% of the total population) had med-
ically controlled hypertension.17 These data are in contrast
to the results of our study, which revealed a greater overall
rate of uncontrolled hypertension (57% in male patients). The
age of our patients was comparable to the age at diagnosis of
hypertension in the patients reported by Branton et al. How-
ever the criteria for diagnosis of hypertension differs
slightly between both studies. As the largest study to date,
the present analysis clearly points to a need for an im-
provement in the awareness of hypertension and its treat-
ment in individuals with Fabry disease.
Enzyme replacement therapy was introduced several
years ago for patients with Fabry disease.18,19 However,
hypertension was considered neither as a risk factor nor as
an outcome in clinical trials of ERT.18–21 In the present
analyses of patients enrolled in FOS, BP readings were
available before the start of ERT, and at 12 months and 24
months of therapy in 60 patients. Uncontrolled hyperten-
sion at baseline was present in 66.7%, after 1 year of
treatment in 46.7%, and after 2 years in 38.3%. A signif-
icant decrease in SBP and DBP was also observed. This
decline in the proportion of patients with uncontrolled
hypertension may not be solely related to ERT, however,
because 29 of the 60 patients were also receiving antihy-
pertensive therapy. Nevertheless, in view of the high costs
of ERT, improvement of BP control and renoprotective
therapy is of the utmost importance for optimal use of
health care resources.
The aim of antihypertensive therapy is the reduction of
cardiovascular and renal morbidity and mortality. In pa-
tients with renal disease, the treatment goal is a BP of
130/80 mm Hg. Both ACEi and ARB have demonstrated
favorable effects on the progression of renal disease.
Among the patients in our cohort with eGFR 90 mL/
min/1.73 m2, only 58 of 276 (21%) used ACE inhibitors or
ARB or a combination of these. There is therefore a need
to improve antihypertensive therapy in patients with Fabry
disease to achieve better outcomes.
Limitations of our study include the fact that BP read-
ings were available in only 391 of 463 adult patients,
which may suggest some selection bias. Furthermore the
BP levels entered into the database by the participating
FOS investigator are not validated by repeated measure-
ments in many instances. Finally, the observation of a
decrease in SBP and DBP during ERT was uncontrolled
and therefore hypothesis generating.
The results of our study show that BP control and reno-
protective therapy are underused among patients with Fabry
disease who have a high prevalence of uncontrolled hyper-
tension and impaired kidney function. Thus our data pave the
way for future trials that should explore the potential of
improved BP control on clinical outcomes in patients with
Fabry disease.References
1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL,
Laster L: Enzymatic defect in Fabry’s disease. Ceramidetrihexosi-
dase deficiency. N Engl J Med 1967;276:1163–1167.
2. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Gold-
man M, Grabowski G, Packman S, Wilcox WR: Fabry disease, an
under-recognized multisystemic disorder: expert recommendations
for diagnosis, management, and enzyme replacement therapy. Ann
Intern Med 2003;138:338–346.
3. MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease:
clinical manifestations and impact of disease in a cohort of 60
obligate carrier females. J Med Genet 2001;38:769–775.
4. Whybra C, Kampmann C, Willers I, Davies J, Winchester B,
Kriegsmann J, Bruhl K, Gal A, Bunge S, Beck M: Anderson-Fabry
disease: clinical manifestations of disease in female heterozygotes.
J Inherit Metab Dis 2001;24:715–724.
5. Alroy J, Sabnis S, Kopp JB: Renal pathology in Fabry disease. J Am
Soc Nephrol 2002;13(Suppl 2):S134–S138.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA,
Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella
EJ: The Seventh Report of the Joint National Committee on Pre-
vention, Detection, Evaluation, and Treatment of High Blood Pres-
sure: the JNC 7 report. J Am Med Assoc 2003;289:2560–2572.
7. K/DOQI clinical practice guidelines on hypertension and antihyper-
tensive agents in chronic kidney disease. Am J Kidney Dis 2004;
43(Suppl 1):S65–S230.
8. 2003 European Society of Hypertension–European Society of Car-
diology guidelines for the management of arterial hypertension.
J Hypertens 2003;21:1011–1053.
9. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A,
Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M:
Fabry disease defined: baseline clinical manifestations of 366 pa-
tients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236–
242.
10. Levey AS: Clinical practice. Nondiabetic kidney disease. N Engl
J Med 2002;347:1505–1511.
11. National Kidney Foundation (NKF) Kidney Disease Outcome Qual-
ity Initiative (K/DOQI) Advisory Board: K/DOQI clinical practice
guidelines for chronic kidney disease: evaluation, classification, and
stratification. Kidney Disease Outcome Quality Initiative. Am J
Kidney Dis 2002;39(Suppl 2):S1–246.
12. Lewington S, Clark R, Qizilbash N, Peto R, Collins R: Age-specific
relevance of usual blood pressure to vascular mortality. Lancet
2002;360:1903–1913.
13. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford
CE, Shulman NB, Stamler J: Blood pressure and end-stage renal
disease in men. N Engl J Med 1996;334:13–18.
14. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW,
Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-
Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D,
Vescio F: Hypertension prevalence and blood pressure levels in 6
European countries, Canada, and the United States. J Am Med
Assoc 2003;289:2363–2369.
15. MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease:
clinical manifestations and impact of disease in a cohort of 98
hemizygous males. J Med Genet 2001;38:750–760.
16. Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores
GM, Obrador GT: Patients with Fabry disease undergoing dialysis
in the United States. Kidney Int 2002;61:249–255.
17. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM,
Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp
JB: Natural history of Fabry renal disease: influence of alpha-
galactosidase A activity and genetic mutations on clinical course.
Medicine 2002;81:122–138.
787AJH–August 2006–VOL. 19, NO. 8 HYPERTENSION IN FABRY DISEASE18. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S,
Caplan L, Linthorst GE, Desnick RJ: Safety and efficacy of recom-
binant human alpha-galactosidase A replacement therapy in Fabry’s
disease. N Engl J Med 2001;345:9–16.
19. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel
T, Balow JE, Brady RO: Enzyme replacement therapy in Fabry disease:
a randomized controlled trial. J Am Med Assoc 2001;285:2743–2749.
20. Beck M, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A,
Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ra-
maswami U, Gal A, Mehta A: Fabry disease: overall effects of
agalsidase treatment. Eur J Clin Invest 2004;34:838–844.
21. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst
GE, Desnick RJ, Germain DP: Long-term safety and efficacy of
enzyme replacement therapy for Fabry disease. Am J Hum Genet
2004;75:65–74.
Appendix
The following investigators submitted data from their pa-
tients to the Fabry Outcome Survey (FOS) database:
Austria: O. Bodamer, A.-C. Hauser, J. Kleinert and G.
Sunder-Plassmann (Vienna), and P. Kotanko, T. Kroepfl,
and B. Plecko (Graz); Belgium: G. Clerbaux, B. Georges,
M.C. Nassogne, and Y. Pirson (Brussels), F. Dehout, D.
Roland and L. Van Maldergem (Charleroi), and K. De
Smet and F. Eyskens (Middelheim); Czech Republic: J.
Bultas, D. Karetová, A. Linhart, J.C. Lubanda and S.
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rari and B. Vogt (Bern), F. Barbey and J. Theytaz (Lausanne),
and G. Schulthess, K. Walter and U. Widmer (Zurich); United
Kingdom: T.M. Cox, P. Deegan, U. Ramaswami, and N. Wright
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